Although glucagon-like peptide-1 (GLP-1) therapy has been associated with the treatment of type 2 diabetes [7, 8], the ability of GLP-1 to activate pro-survival pathways is well known [9]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.